US 12,168,785 B2
Recombinant KOD polymerase
Lili Zhai, Shenzhen (CN); Lin Wang, Shenzhen (CN); Wenwei Zhang, Shenzhen (CN); Yuliang Dong, Shenzhen (CN); Yue Zheng, Shenzhen (CN); and Fen Liu, Shenzhen (CN)
Assigned to BGI SHENZHEN, Shenzhen (CN)
Appl. No. 17/270,489
Filed by BGI SHENZHEN, Shenzhen (CN)
PCT Filed Sep. 3, 2018, PCT No. PCT/CN2018/103764
§ 371(c)(1), (2) Date Feb. 23, 2021,
PCT Pub. No. WO2020/047695, PCT Pub. Date Mar. 12, 2020.
Prior Publication US 2021/0324353 A1, Oct. 21, 2021
Int. Cl. C12Q 1/68 (2018.01); C12N 9/12 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6869 (2018.01)
CPC C12N 9/1252 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/6869 (2013.01); C12Y 207/07007 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A protein, which is A) or B) as follows:
A) a protein that has DNA polymerase activity obtained by substituting the following of wild-type KOD DNA polymerase:
the valine at position 389 with isoleucine; the valine at position 589 with histidine; the threonine at position 676 with lysine; the valine at position 680 with methionine; the serine at position 383 with threonine; the tyrosine at position 384 with phenylalanine;
B) a protein derived from A) that has DNA polymerase activity by adding a tag sequence to the end of the amino acid sequence of the protein shown in A);
wherein the amino acid sequence of wild-type KOD DNA polymerase is shown in SEQ ID NO: 1.